TABLE 5. Reported cases of notifiable diseases and rates per 100,000, by sex, excluding U.S. territories - - United States, 2016

(Accessible Version: https://wonder.cdc.gov/nndss/static/2016/annual/2016-table5.html)

Disease	Fema	Female		le	Sex not stated	Total
	No.	Rate	No.	Rate	No.	No.
Anthrax	_	_	_	_	_	_
Arboviral diseases						
Chikungunya virus disease	134	0.08	113	0.07	_	247
Eastern equine encephalitis virus disease						
Neuroinvasive	1	0.00	6	0.00	_	7
Non-neuroinvasive	_	_	_	_	_	_
Jamestown Canyon virus disease						
Neuroinvasive	2	0.00	5	0.00	_	7
Non-neuroinvasive	1	0.00	7	0.00	_	8
La Crosse virus disease						
Neuroinvasive	10	0.01	21	0.01	_	31
Non-neuroinvasive	_	_	4	0.00	_	4
Powassan virus disease						
Neuroinvasive	7	0.00	14	0.01	_	21
Non-neuroinvasive	1	0.00	_	_	_	1
St. Louis encephalitis virus disease						
Neuroinvasive	3	0.00	4	0.00	_	7
Non-neuroinvasive	_	_	1	0.00	_	1
West Nile virus disease						
Neuroinvasive	463	0.28	845	0.53	_	1,308
Non-neuroinvasive	362	0.22	479	0.30	_	841
Western equine encephalitis virus disease						
Neuroinvasive	_	_	_	_	_	_
Non-neuroinvasive	_	_	_	_	_	_
Babesiosis						
Total	659	0.57	1,246	1.10	5	1,910
Confirmed	536	0.46	1,045	0.92	4	1,585
Probable	123	0.11	201	0.18	1	325
Botulism		***				
Total	82	0.05	118	0.07	1	201
Foodborne	7	0.00	24	0.02		31
Infant *	67	3.45	76	3.74	1	144
Other (wound & unspecified)	8	0.00	18	0.01	·	26
Brucellosis	49	0.03	77	0.01	1	127
Campylobacteriosis		17.31		19.75	298	60,120
Chancroid	28,398	0.00	31,424	0.00	290	
					2765	1 500 354
Chlamydia trachomatis infection Cholera	1,072,719	653.90	522,870	328.69 0.00	2,765	1,598,354 15
		0.00	7		_	
Coccidioidomycosis †	5,106	7.70	6,701	10.33	22	11,829
Cryptosporidiosis						
Total	6,904	4.21	6,454	4.06	95	13,453
Confirmed	4,346	2.65	4,254	2.67	37	8,637
Probable	2,558	1.56	2,200	1.38	58	4,816
Cyclosporiasis	325	0.22	211	0.15	1	537
Dengue virus infections §						
Dengue	447	0.27	456	0.29	_	903
Dengue-like illness	16	0.01	24	0.02	_	40
Severe dengue	4	0.00	6	0.00	_	10
Diphtheria	_	_	_		_	_
Ehrlichiosis and Anaplasmosis						
Anaplasma phagocytophilum infection	1,596	1.01	2,473	1.61	82	4,151
Ehrlichia chaffeensis infection	529	0.33	846	0.55	2	1,377

TABLE 5. Reported cases of notifiable diseases and rates per 100,000, by sex, excluding U.S. territories - - United States, 2016

(Accessible Version: https://wonder.cdc.gov/nndss/static/2016/annual/2016-table5.html)

	Fema	Female		le	Sex not stated	Total
Disease	No.	Rate	No.	Rate	No.	No.
Ehrlichia ewingii infection	11	0.01	11	0.01	_	22
Undetermined ehrlichiosis/anaplasmosis	96	0.06	104	0.07	_	200
Giardiasis	6,490	5.04	9,770	7.82	50	16,310
Gonorrhea	197,499	120.39	270,033	169.75	982	468,514
Haemophilus influenzae, invasive disease						
All ages, all serotypes	2,634	1.61	2,233	1.40	28	4,895
Age <5 years ¶						
Serotype b	11	0.11	19	0.19	_	30
Non-b serotype	67	0.69	92	0.90	_	159
Nontypeable	89	0.91	106	1.04	1	196
Unknown serotype	83	0.85	103	1.01	1	187
Hansen's disease	17	0.01	46	0.03	15	78
Hantavirus infection, non-hantavirus pulmonary syndrome	2	0.00	4	0.00	_	6
Hantavirus pulmonary syndrome	13	0.01	18	0.01	_	31
Hemolytic uremic syndrome post-diarrheal	181	0.11	125	0.08	1	307
Hepatitis **						
A, acute	897	0.55	1,107	0.70	3	2,007
B, acute	1,252	0.77	1,957	1.24	9	3,218
B, perinatal infection ^{††}	11	0.28	21	0.52	_	32
C, acute	1,310	0.85	1,627	1.08	5	2,942
Human immunodeficiency virus diagnoses	6,631	4.04	28,144	17.69	_	34,775
Influenza-associated pediatric mortality §§	48	0.13	34	0.09	_	82
Invasive pneumococcal disease	10	0.13	31	0.03		
All ages	8,400	6.86	9,125	7.71	101	17,626
Confirmed	8,390	6.85	9,112	7.71	101	17,623
Probable	10	0.03	13	0.01	101	23
Age <5 years ¶	484	0.37	652	0.51	6	1,142
9						
Confirmed Probable	481	6.17	650	7.98	6	1,137
		0.04		0.02	_	5
Legionellosis	2,458	1.50	3,679	2.31	4	6,141
Leptospirosis	401	0.01	60 383	0.05	_	78
Listeriosis	401	0.24	383	0.24	2	786
Lyme disease	15 207	0.27	20.567	12.00		26 420
Total Confirmed	15,307	9.37	20,567	12.99	555	36,429
Probable	10,971	6.72	14,810	9.35	422	26,203
Malaria	4,336 743	2.65	5,757	3.64	133	10,226
	/43	0.45	1,194	0.75	18	1,955
Measles Total	24	0.01	61	0.04		0.
	19	0.01	49	0.04	_	85 68
Indigenous Imported	5	0.00	12	0.03	_	17
·	5	0.00	12	0.01	_	17
Meningococcal disease	173	0.11	202	0.12		275
All serogroups		0.11	202	0.13	_	375
Serogroup R	62	0.04	64	0.04	_	126
Serogroup B	41	0.02	45	0.03	_	86 21
Other serogroups	61	0.01	12 81	0.01	_	142
Unknown serogroup						
Mumps Novel Influenza A virus infections	3,147	1.92	3,194	2.01	28	6,369
	9	0.01	9.020	0.01		17.073
Pertussis	9,900	6.03	8,029	5.05	43	17,972
Plague	_	_	4	0.00	_	4
Poliomyelitis, paralytic	-	_	_	_	_	
Poliovirus infection, nonparalytic	_	- 0.04		-	_	
Psittacosis	8	0.01	4	0.00	_	12

TABLE 5. Reported cases of notifiable diseases and rates per 100,000, by sex, excluding U.S. territories - - United States, 2016

(Accessible Version: https://wonder.cdc.gov/nndss/static/2016/annual/2016-table5.html)

Disease	Female		Ма	le	Sex not stated	Total
	No.	Rate	No.	Rate	No.	No.
Q fever						
Total	34	0.02	130	0.08	_	164
Acute	27	0.02	105	0.07	_	132
Chronic	7	0.00	25	0.02	_	32
Rabies						
Human	_	_	_	_	_	_
Rubella	_	_	1	0.00	_	1
Rubella, congenital syndrome *	2	0.10	_	_	_	2
Salmonellosis	28,379	17.30	25,090	15.77	381	53,850
Severe acute respiratory syndrome-associated coronavirus disease	_	_	_	_	_	_
Shiga toxin-producing <i>Escherichia coli</i> ¶¶	4,521	2.76	3,614	2.27	34	8,169
Shigellosis	10,579	6.45	10,359	6.51	159	21,097
Smallpox	_	_	_		_	
Spotted fever rickettsiosis						
Total	1,442	0.88	2,823	1.79	4	4,269
Confirmed	46	0.03	108	0.07	_	154
Probable	1,396	0.86	2,715	1.72	4	4,115
Streptococcal toxic shock syndrome	146	0.14	137	0.13		283
Syphilis Syphilis	110	0.11	137	0.13		
Total, all stages ***	14,848	9.05	72,433	45.53	761	88,042
	14,040	9.05	72,433	45.55		
Congenital *	_	_			628	628
Primary and secondary	3,049	1.86	24,724	15.54	41	27,814
Tetanus	11	0.01	22	0.01	1	34
Toxic shock syndrome (other than Streptococcal)	28	0.02	11	0.01	1	40
Trichinellosis	6	0.00	20	0.01	_	26
Tuberculosis	3,633	2.21	5,639	3.54	_	9,272
Tularemia	76	0.05	153	0.10	1	230
Typhoid fever	177	0.11	197	0.12	2	376
Vancomycin-intermediate Staphylococcus aureus	46	0.04	62	0.05	_	108
Vancomycin-resistant Staphylococcus aureus	_	_	_		_	
Varicella morbidity	4,330	3.28	4,581	3.58	42	8,953
Varicella mortality	U	U	U	U	U	U
Vibriosis						
Total	437	0.27	824	0.53	12	1,273
Confirmed	422	0.26	807	0.52	12	1,241
Probable	15	0.01	17	0.01	_	32
Viral hemorrhagic fevers						
Crimean-Congo hemorrhagic fever virus	_	_	_	_	_	_
Ebola virus	_	_	_	_	_	_
Guanarito virus	_	_	_	_	_	_
Junin virus	_	_	_	_	_	_
Lassa virus	_	_	_	_	_	_
Lujo virus	_	_	_	_	_	_
Machupo virus	_	_	_	_	_	_
Marburg virus	_	_	_	_	_	_
Sabia virus	_	_	_	_	_	_
Yellow fever	_	_	1	0.00	_	1
Zika virus						
Zika virus disease, congenital *,†††	17	0.88	13	0.64	_	30
Zika virus disease, non-congenital	3,290	2.01	1,842	1.16	_	5,132
Zika virus infection, congenital *, ^{†††}	23	1.19	22	1.08	_ -	45
zika virus infection, congenitai		1.19		1.00	_	43

^{—:} No reported cases — The reporting jurisdiction did not submit any cases to CDC. U: Unavailable — The data are unavailable.

- * The rate is calculated using population less than 1 year of age.
- + Reportable in <25 states.
- § Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).
- ¶ The rate is calculated using population less than 5 years of age.
- ** Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm.
- ++ The rate is calculated using population less than 2 years of age.
- §§ The rate is calculated using population less than 18 years of age.
- ¶¶ Includes Escherichia coli O157:H7; shiga toxin-positive, serogroup non-O157; and shiga toxin positive, not serogrouped.
- *** Includes syphilis of all stages, including cases where stage of syphilis is not stated.
- ### Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/zika/reporting/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.

Notes:

- These are **annual** cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
- The list of nationally notifiable infectious diseases and conditions for 2016 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2016" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2015 by CSTE for national surveillance, that were implemented in January 2016, including updated surveillance case definitions for acute hepatitis C and chronic hepatitis C virus infections. 2016 data are reported through June 30, 2017. Publication criteria for the finalized 2016 data are available at /nndss/documents/2016_NNDSS_Publication_Criteria.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
- Population estimates for incidence rates are July 1st, 2016 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for July 1, 2011 July 1, 2016, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2016), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states as of June 26, 2017 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2016 mid-year estimates from the U.S. Census Bureau International Data Base accessed on July 24, 2017 at https://www.census.gov/population/international/data/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
- Annual tables for 2016 and later years are available on CDC WONDER.
- Annual summary reports from 1993-2015 are available as published in the MMWR.
- NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left).

Suggested Citation:

Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2016 Annual Tables of Infectious Disease Data.
 Atlanta, GA. CDC Division of Health Informatics and Surveillance, 2017. Available at: https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html.

National Notifiable Diseases Surveillance System

Provided by CDC WONDER